Vimarsana
Biggest News Aggregation in the World

Study Treatment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Study Treatment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Study Treatment Today - Breaking & Trending Today

Theralase Technologies Inc.: Theralase Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements - Vimarsana News

Theralase Technologies Inc.: Theralase Releases Corrected and Restated Press Release for 1Q2023 Interim Financial Statements

In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release.TORONTO, ON / ACCESSWIRE / May 30, 2023 / Theralase®

Theralase Technologies Inc.: Theralase Releases 1Q2023 Interim Financial Statements - Vimarsana News

Theralase Technologies Inc.: Theralase Releases 1Q2023 Interim Financial Statements

TORONTO, ON / ACCESSWIRE / May 30 2023 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development

Theralase Provides Update on Phase II Bladder Cancer Study - Vimarsana News

Theralase Provides Update on Phase II Bladder Cancer Study

Theralase Provides Update on Phase II Bladder Cancer Study

Theralase® Releases FY2022 Audited Financial Statements - Vimarsana News

Theralase® Releases FY2022 Audited Financial Statements

TORONTO, April 26, 2023 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage...

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19 - Vimarsana News

Pardes Biosciences Announces Top-line Results from Phase 2 Trial Evaluating Pomotrelvir for the Treatment of COVID-19

03.04.2023 - Pomotrelvir did not meet the primary endpoint measured by proportion of participants below the limit of detection for infectious SARS-CoV-2 on day 3 of treatment with pomotrelvir vs. placebo Otherwise healthy, vaccinated adults without risk factors ...